Related Experiment Video

Updated: Mar 30, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.3K

CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition

Elizabeth I Buchbinder1, Anupam Desai

  • 1*Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School †Biologic Therapy Program, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.

American Journal of Clinical Oncology
|November 13, 2015
PubMed

Insights

Immune checkpoints like cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) regulate T-cell function. Inhibiting these checkpoints offers new cancer immunotherapies for melanoma and lung cancer.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) are key immune checkpoints that suppress T-cell activity.
  • Their inhibition has revolutionized cancer treatment, leading to approved immunotherapies for melanoma and non-small cell lung cancer.

Purpose of the Study:

  • To provide an overview of the CTLA-4 and PD-1 pathways.
  • To discuss the implications of inhibiting these pathways in cancer therapy.
  • To highlight the distinct roles of CTLA-4 and PD-1 in immune regulation.

Main Methods:

  • Literature review of CTLA-4 and PD-1 pathways.
  • Analysis of approved immunotherapies targeting these checkpoints.
  • Comparison of the mechanistic differences between CTLA-4 and PD-1 inhibition.

Main Results:

  • CTLA-4 regulates T-cell proliferation early in immune responses, primarily in lymph nodes.
  • PD-1 suppresses T cells later in immune responses, mainly in peripheral tissues.
  • Distinct roles suggest varying clinical profiles for immunotherapies targeting CTLA-4 and PD-1.

Conclusions:

  • Understanding the distinct roles of CTLA-4 and PD-1 is crucial for optimizing cancer immunotherapy strategies.
  • Inhibition of CTLA-4 and PD-1 represents a significant advancement in treating various cancers.
  • Further research into the mechanistic differences can refine therapeutic approaches.

More Related Videos

In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function09:26

In Vitro Assay to Evaluate the Impact of Immunoregulatory Pathways on HIV-specific CD4 T Cell Effector Function

Published on: October 15, 2013

14.6K
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.7K

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.2K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.9K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
17.4K